On Monday, Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) was 13.90% up from the session before settling in for the closing price of $13.31. A 52-week range for BCYC has been $12.17 – $28.67.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 24.55%. When this article was written, the company’s average yearly earnings per share was at 40.58%. With a float of $65.57 million, this company’s outstanding shares have now reached $69.02 million.
Let’s determine the extent of company efficiency that accounts for 284 employees. In terms of profitability, gross margin is 80.59%, operating margin of -595.3%, and the pretax margin is -521.23%.
Bicycle Therapeutics Plc ADR (BCYC) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Bicycle Therapeutics Plc ADR stocks. The insider ownership of Bicycle Therapeutics Plc ADR is 4.99%, while institutional ownership is 62.74%. The most recent insider transaction that took place on Jan 06 ’25, was worth 40,290. In this transaction CHIEF ACCOUNTING OFFICER of this company sold 2,686 shares at a rate of $15.00, taking the stock ownership to the 32,146 shares. Before that another transaction happened on Jan 02 ’25, when Company’s CHIEF ACCOUNTING OFFICER sold 1,750 for $14.09, making the entire transaction worth $24,658. This insider now owns 34,991 shares in total.
Bicycle Therapeutics Plc ADR (BCYC) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.85 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 40.58% per share during the next fiscal year.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Trading Performance Indicators
You can see what Bicycle Therapeutics Plc ADR (BCYC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 17.13. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 28.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.30, a number that is poised to hit -0.86 in the next quarter and is forecasted to reach -3.52 in one year’s time.
Technical Analysis of Bicycle Therapeutics Plc ADR (BCYC)
Looking closely at Bicycle Therapeutics Plc ADR (NASDAQ: BCYC), its last 5-days average volume was 0.37 million, which is a drop from its year-to-date volume of 0.41 million. As of the previous 9 days, the stock’s Stochastic %D was 42.69%. Additionally, its Average True Range was 1.13.
During the past 100 days, Bicycle Therapeutics Plc ADR’s (BCYC) raw stochastic average was set at 18.12%, which indicates a significant decrease from 86.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 72.43% in the past 14 days, which was lower than the 86.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.96, while its 200-day Moving Average is $22.11. However, in the short run, Bicycle Therapeutics Plc ADR’s stock first resistance to watch stands at $15.73. Second resistance stands at $16.31. The third major resistance level sits at $17.45. If the price goes on to break the first support level at $14.02, it is likely to go to the next support level at $12.88. Should the price break the second support level, the third support level stands at $12.30.
Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Key Stats
There are 69,046K outstanding shares of the company, which has a market capitalization of 1.05 billion. As of now, sales total 26,980 K while income totals -180,660 K. Its latest quarter income was 2,680 K while its last quarter net income were -50,800 K.
